Suppr超能文献

骨质疏松症的治疗方法可以提高低骨量患者的骨材料强度指数。

Treatments of osteoporosis increase bone material strength index in patients with low bone mass.

机构信息

Center for Bone Quality, Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Osteoporos Int. 2020 Sep;31(9):1683-1690. doi: 10.1007/s00198-020-05375-3. Epub 2020 Apr 8.

Abstract

UNLABELLED

Effects on bone material properties of two-year antiosteoporotic treatment were assessed using in vivo impact microindentation (IMI) in patients with low bone mineral density (BMD) values. Antiresorptive treatment, in contrast to vitamin D ± calcium treatment alone, induced BMD-independent increases in bone material strength index, measured by IMI, the magnitude of which depended on pretreatment values.

INTRODUCTION

Bone material strength index (BMSi), measured by IMI in vivo, is reduced in patients with fragility fractures, but there is no information about changes in values during long-term therapy. In the present study, we assessed changes in BMSi in patients receiving antiosteoporotic treatments for periods longer than 12 months.

METHODS

We included treatment-naive patients with low bone mass who had a BMSi measurement with OsteoProbe® at presentation and consented to a repeat measurement after treatment.

RESULTS

We studied 54 patients (34 women), median age 58 years, of whom 30 were treated with bisphosphonates or denosumab (treatment group) and 24 with vitamin D ± calcium alone (control group). There were no differences in clinical characteristics between the two groups with the exception of a higher number of previous fragility fractures in the treatment group. Baseline hip BMD and BMSi values were lower in the treatment group. After 23.1 ± 6.6 months, BMSi increased significantly in the treatment group (82.4 ± 4.3 vs 79.3 ± 4.1; p < 0.001), but did not change in the control group (81.5 ± 5.2 vs 82.2 ± 4.1; p = 0.35). Changes in BMSi with antiresorptives were inversely related with baseline values (r = - 0.43; p = 0.02) but not with changes in BMD. Two patients in the control group with large decreases in BMSi values sustained incident fractures.

CONCLUSION

In patients at increased fracture risk, antiresorptive treatments induced BMD-independent increases in BMSi values, the magnitude of which depended on pretreatment values.

摘要

目的

采用体内冲击微压痕(IMI)技术评估两年抗骨质疏松治疗对骨材料特性的影响,该研究对象为骨密度(BMD)值较低的患者。与单独使用维生素 D±钙治疗相比,抗吸收治疗可使 IMI 测量的骨材料强度指数(BMSi)增加,且增加幅度与治疗前的数值有关。

简介

在脆性骨折患者中,IMI 测量的骨材料强度指数(BMSi)降低,但关于长期治疗过程中该数值的变化情况,尚无相关信息。在本研究中,我们评估了接受抗骨质疏松治疗 12 个月以上的患者的 BMSi 值变化情况。

方法

我们纳入了治疗初治且初次就诊时进行了 OsteoProbe®骨材料强度指数测量、并同意再次进行治疗后测量的低骨量患者。

结果

共纳入 54 例患者(34 例女性),中位年龄 58 岁,其中 30 例接受双膦酸盐或地舒单抗治疗(治疗组),24 例接受维生素 D±钙治疗(对照组)。除治疗组有更多的既往脆性骨折外,两组的临床特征无差异。治疗组的基线髋部 BMD 和 BMSi 值较低。经过 23.1±6.6 个月后,治疗组的 BMSi 显著增加(82.4±4.3 比 79.3±4.1;p<0.001),而对照组无变化(81.5±5.2 比 82.2±4.1;p=0.35)。抗吸收药物治疗后 BMSi 的变化与基线值呈负相关(r=-0.43;p=0.02),但与 BMD 的变化无关。对照组中,2 例 BMSi 值大幅下降的患者发生了新发骨折。

结论

在骨折风险增加的患者中,抗吸收治疗可使 IMI 测量的 BMSi 值增加,且增加幅度与治疗前的数值有关,与 BMD 无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验